StreetInsider.com News Articles

Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26

Thu, 15 Oct 2026 08:00:00 -0400

FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care.

Key Highlights:

Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators
Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care
Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026)

OAK RIDGE, Tenn., Oct.

Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26

Thu, 15 Oct 2026 08:00:00 -0400

FDA-cleared BVA™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care.

Key Highlights:

Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators
Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care
Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026)

OAK RIDGE, Tenn., Oct.

Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26

Thu, 15 Oct 2026 08:00:00 -0400

FDA-cleared BVA^™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care.

Key Highlights:

Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators
Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care
Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026)

OAK RIDGE,

Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26

Thu, 15 Oct 2026 08:00:00 -0400

FDA-cleared BVA^™ technology delivers lab-accurate precision to optimize cardiovascular service lines, reduce 30-day readmissions, and lower cost of care.

Key Highlights:

Commercial Acceleration: Daxor showcasing its next-generation Blood Volume Analyzer (BVA) platform to executive service line leaders and cardiovascular administrators
Operational & Economic Impact: Demonstrating how direct volume measurement eliminates subjective estimation, shortens length of stay, and targets key value-based metrics in cardiac care
Executive Presence: Commercial leadership hosting platform demonstrations at the MedAxiom CV Transforum Fall '26 in Denver, CO (October 22–24, 2026)

OAK RIDGE,

Daxor shares new heart failure data from HFSA 2026 meeting

Wed, 14 Oct 2026 08:04:03 -0400

Daxor Corporation (Nasdaq: DXR) reported clinical study results and clinician engagement following the Heart Failure Society of America 2026 Annual Scientific Meeting, according to a company statement.
Researchers from Banner University Medical Center presented two studies examining Daxor's blood volume analysis (BVA) technology in heart failure patients.
The first study, focused on patients with left ventricular assist devices and total artificial hearts, found that standard bedside examinations missed fluid overload and anemia in 38% of cases. The study reported that direct BVA measurement produced a statistically significant improvement in patient diuresis (p = 0.02).
The second study, involving 238 patients with advanced heart

Daxor shares new heart failure data from HFSA 2026 meeting

Wed, 14 Oct 2026 08:04:03 -0400

Daxor Corporation (Nasdaq: DXR) reported clinical study results and clinician engagement following the Heart Failure Society of America 2026 Annual Scientific Meeting, according to a company statement.
Researchers from Banner University Medical Center presented two studies examining Daxor's blood volume analysis (BVA) technology in heart failure patients.
The first study, focused on patients with left ventricular assist devices and total artificial hearts, found that standard bedside examinations missed fluid overload and anemia in 38% of cases. The study reported that direct BVA measurement produced a statistically significant improvement in patient diuresis (p = 0.02).
The second study, involving 238 patients with advanced heart

Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026

Wed, 14 Oct 2026 08:00:00 -0400

New Clinical Studies Validate BVA^™ Technology in High-Acuity Heart Failure Populations to Enhance Care

OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.

Strong clinician engagement at the conference underscored the need for Daxor’s next-generation blood volume analysis (BVA^™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%. Daxor

Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026

Wed, 14 Oct 2026 08:00:00 -0400

New Clinical Studies Validate BVA^™ Technology in High-Acuity Heart Failure Populations to Enhance Care

OAK RIDGE, TN, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced significant clinician interest and compelling clinical validation following the Heart Failure Society of America (HFSA) 2026 Annual Scientific Meeting.

Strong clinician engagement at the conference underscored the need for Daxor’s next-generation blood volume analysis (BVA^™) radiopharmaceutical diagnostic system, driven by its streamlined workflow, rapid result delivery, and industry-leading accuracy exceeding 95%. Daxor

Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026

Tue, 13 Oct 2026 08:00:00 -0400

Making its ASN debut, Daxor’s BVA^™technology delivers precise volume measurement to optimize fluid management and improve complex kidney care.

Key Highlights:

Commercial Presence: Daxor exhibiting at Booth #390 during ASN Kidney Week 2026 in Denver, CO (October 21–25, 2026).

Clinical Focus: Highlighting Blood Volume Analysis (BVA) to address critical fluid overload, cardiorenal syndrome, and dialysis volume management challenges.

Global Reach: Engaging with international nephrology leaders to advance data-driven precision medicine for patients with renal disease.

OAK RIDGE, Tenn., Oct. 13,

Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026

Tue, 13 Oct 2026 08:00:00 -0400

Making its ASN debut, Daxor’s BVA^™technology delivers precise volume measurement to optimize fluid management and improve complex kidney care.

Key Highlights:

Commercial Presence: Daxor exhibiting at Booth #390 during ASN Kidney Week 2026 in Denver, CO (October 21–25, 2026).

Clinical Focus: Highlighting Blood Volume Analysis (BVA) to address critical fluid overload, cardiorenal syndrome, and dialysis volume management challenges.

Global Reach: Engaging with international nephrology leaders to advance data-driven precision medicine for patients with renal disease.

OAK RIDGE, Tenn., Oct. 13,

Form 40-8F-2/A DAXOR CORP

Fri, 09 Oct 2026 17:02:00 -0400
si-local-file:///var/storage/secattach/20261009/27172186.html

Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

Thu, 01 Oct 2026 08:00:00 -0400

FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management.

Key Highlights:

Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA^™) designed for rapid clinical adoption across hospital systems and outpatient clinics
Clinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patients
On-Site Demonstrations: Daxor participating in HFSA’s dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October

Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026

Thu, 01 Oct 2026 08:00:00 -0400

FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management.

Key Highlights:

Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA^™) designed for rapid clinical adoption across hospital systems and outpatient clinics
Clinical Evidence: Independent clinical investigators to present two ePosters highlighting how BVA addresses volume derangements in complex heart failure, LVAD, and total artificial heart patients
On-Site Demonstrations: Daxor participating in HFSA’s dedicated Device Day and exhibiting at Booth #803 in Phoenix, AZ (October

Form N-CEN/A DAXOR CORP For: Dec 31

Thu, 24 Sep 2026 17:17:00 -0400
si-local-file:///var/storage/secattach/20260924/27102933.html

Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

Tue, 08 Sep 2026 17:40:00 -0400

Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026.

Management will host one-on-one and small group meetings with investors. For more information about the event or questions about registration, interested parties should reach out to their contacts at Lake Street.

Interested investors may also contact Bret Shapiro

Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference

Tue, 08 Sep 2026 17:40:00 -0400

Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026.

Management will host one-on-one and small group meetings with investors. For more information about the event or questions about registration, interested parties should reach out to their contacts at Lake Street.

Interested investors may also contact Bret Shapiro

Daxor Corp. (DXR) PT Lowered to $18 at Lake Street

Tue, 01 Sep 2026 13:05:13 -0400

Lake Street analyst Frank Takkinen lowered the price target on Daxor Corp. (NASDAQ: DXR) to $18.00 (from $23.00) while maintaining a Buy rating.

Daxor reports 16% kit sales growth in first half of 2026

Tue, 01 Sep 2026 08:00:42 -0400

Daxor Corporation (Nasdaq: DXR) issued a shareholder letter from CEO and President Michael Feldschuh providing a financial and operational update for the six months ended June 30, 2026.

Unaudited kit sales grew 16% in the first half of 2026 compared with the prior-year period. The company completed a $9 million registered direct offering in January 2026, issuing 765,958 shares at $11.75 per share. As of June 30, 2026, net assets stood at $51,832,130, up from $45,887,266 at December 31, 2025. Net asset value per share was $8.88 at June 30, 2026, compared with $9.07 at December 31, 2025.

Daxor used a portion

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Tue, 01 Sep 2026 08:00:00 -0400

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

Dear Valued Shareholders,

“It’s still Day 1.” — Jeff Bezos
That's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our clinical data, our acquisition of our supplier, Isotex Diagnostics, our capital raise

Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter

Tue, 01 Sep 2026 08:00:00 -0400

Oak Ridge, TN, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today provides a mid-year corporate and financial update in a Letter to Shareholders from CEO and President Michael Feldschuh.

Dear Valued Shareholders,

“It’s still Day 1.” — Jeff Bezos
That's exactly how we think about where Daxor stands today. Everything we have accomplished to date — the FDA clearance of our next-generation analyzer, our new patent, our clinical data, our acquisition of our supplier, Isotex Diagnostics, our capital raise

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas

Wed, 29 Jul 2026 22:40:00 -0400

Commercial Momentum Accelerates as Health System Adopts Turnkey Blood Volume Analysis via CLIA-Certified Send-Out Model

OAK RIDGE, TN, July 29, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced the launch of a new outpatient Blood Volume Analysis (BVA^™) program at a leading healthcare facility in eastern Kansas. This initiative expands Daxor’s presence in Midwestern outpatient care, giving regional clinicians direct access to objective volume metrics.

The launch leverages Daxor’s turnkey ezBVA Lab send-out model, enabling outpatient practices to obtain 98% accurate, quantitative blood

Daxor to exhibit blood volume analyzer at dysautonomia conference

Tue, 07 Jul 2026 08:03:06 -0400

Daxor Corporation (NASDAQ: DXR) announced it will exhibit for the first time at the 14th Annual Dysautonomia International Conference, scheduled for July 9–12, 2026, at The Woodlands Marriott Waterway Hotel & Convention Center in The Woodlands, Texas.
The Oak Ridge, Tennessee-based company plans to display its FDA-cleared Blood Volume Analyzer (BVA), a lab-based diagnostic device designed to measure plasma and red blood cell volumes. The conference brings together physicians, researchers, clinicians, and patient advocates focused on autonomic disorders.
"For too long, dysautonomia patients have faced an uphill battle due to the limitations of traditional diagnostics," said John L. Jefferies, MD, MPH, MBA,